Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
Guggenheim has reiterated its 'Buy' rating for Eli Lilly and Company (LLY) but has slightly reduced its price target to $1,161. This adjustment indicates continued confidence in the stock's performance despite a minor revision to the target price. Investors will likely view this as a positive signal for Eli Lilly's prospects.
Guggenheim has reduced its price target for Eli Lilly and Company (LLY) to $1,161 from $1,163, while maintaining a 'Buy' rating. This adjustment follows a routine model update in anticipation of the company's Q4 results. The FDA recently granted Breakthrough Therapy designation to Eli Lilly's sofetabart mipitecan, an oncology drug, which is expected to accelerate its development and enhance the company's pipeline visibility.
Y Intercept Hong Kong Ltd significantly increased its stake in Amgen Inc. by 97.9% in Q3, now holding 33,221 shares valued at approximately $9.375 million. This move follows Amgen's strong Q3 earnings beat, where it surpassed EPS and revenue estimates, and its announcement of an increased quarterly dividend to $2.52 per share. The article also highlights various institutional changes in Amgen holdings, recent analyst ratings, and a mix of positive and negative news impacting the company.
UniSuper Management Pty Ltd reduced its stake in Republic Services, Inc. by 3.5% in the third quarter, selling 6,180 shares and holding 168,276 shares worth $38.62 million. Other institutional investors also adjusted their positions, and a company director recently purchased additional shares. Analyst ratings for Republic Services currently indicate a "Moderate Buy" consensus with an average target price of $248.82.
UniSuper Management Pty Ltd significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 9.4% during the third quarter, bringing its total holdings to 251,394 shares valued at $58.21 million. This move is part of a broader trend of institutional investors modifying their positions in AbbVie, with several other major firms also making substantial adjustments to their holdings. The company recently increased its quarterly dividend and analysts have given it a "Moderate Buy" consensus rating.
Jennison Associates LLC significantly reduced its stake in AstraZeneca PLC by selling 8,481,701 shares, cutting its holding by 69.7% to 3,685,664 shares valued at approximately $282.8 million. Despite this large sale, Wall Street analysts maintain a "Moderate Buy" consensus for AstraZeneca with an average price target of $95.75. The biopharmaceutical company recently exceeded quarterly earnings expectations, reporting an EPS of $1.19 against an estimated $1.14 and revenue of $15.19 billion, an increase of 12% year-over-year.
Envestnet Portfolio Solutions Inc. reduced its stake in Republic Services, Inc. by 11.3% in the third quarter, selling 6,148 shares and leaving them with 48,204 shares valued at $11.06 million. Other institutional investors like Norges Bank and M&G PLC significantly increased their positions in the waste management company. Republic Services reported strong third-quarter earnings, exceeding analyst expectations, and has received a "Moderate Buy" consensus rating from Wall Street analysts.
Ventyx Biosciences' board has approved cash bonus awards for key executives and employees, including CEO Raju Mohan, ahead of its planned merger with Eli Lilly and Company. These bonuses replace the regular 2026 annual equity grants and are contingent on continuous service until the merger closes by April 7, 2027. If the merger doesn't finalize, employees will be recommended to receive company common stock options instead.
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Ventyx Biosciences, Inc. (NasdaqGS: VTYX) to Eli Lilly and Company (NYSE: LLY) for $14.00 per share in cash. KSF seeks to determine if this consideration and the sale process are fair to shareholders or if the Company is undervalued. Shareholders who believe the transaction undervalues Ventyx Biosciences are encouraged to contact KSF to discuss their legal rights.
Indian drugmaker Dr. Reddy’s Laboratories plans to launch a generic version of Novo Nordisk's diabetes drug Ozempic in March, capitalizing on the drug's patent expiration in India. This move is expected to significantly reduce treatment costs for Indian patients with type 2 diabetes and intensify competition in the global market for diabetes and weight-loss drugs. Dr. Reddy's also aims for global expansion, seeking approval for generic Ozempic in key markets like Turkey, Brazil, and Canada, while also pursuing a non-branded version of Wegovy.
The VanEck Pharmaceutical ETF (PPH) has seen significant growth due to its concentrated investment in GLP-1 weight-loss drug manufacturers like Eli Lilly and Novo Nordisk. Analysts project the GLP-1 market to reach over $150 billion by the early 2030s, making PPH a direct play on this expansion. However, the fund faces potential risks from intensifying competition, pricing pressures, and patent cliffs for other holdings.
Astellas' CEO plans to avoid "rescue BD" despite an upcoming patent cliff for Xtandi, focusing on internal research and development. Takeda is laying off 243 neuroscience field employees in the U.S. in preparation for the Trintellix patent expiry, while also creating new roles for future medication launches. Chugai's CEO is aiming for increased name recognition to attract more external partners for its mid- to long-term strategy.
Lockheed Martin Investment Management Co. reduced its stake in Eli Lilly and Company by 70% in the third quarter, selling 27,400 shares and retaining 11,770 shares valued at approximately $8.98 million. The pharmaceutical giant exceeded Q3 earnings expectations with an EPS of $7.02 and revenue of $17.6 billion, while also raising its quarterly dividend and receiving a consensus "Buy" rating from analysts. Positive developments in its oncology and metabolic drug pipelines are noted, though competitive and legal challenges pose risks.
The Teacher Retirement System of Texas reduced its stake in Eli Lilly and Company (LLY) by 4.4% in the third quarter of last year, selling over 13,000 shares. Despite this trim, Eli Lilly remains a significant holding for the Texas pension fund, and institutional ownership of the pharmaceutical giant is high at 82.53%. The company recently reported strong quarterly earnings, raised its dividend, and has received several positive analyst ratings and price target increases.
Spear Holdings RSC Ltd decreased its stake in Eli Lilly and Company by 14.7% in Q3 2025, selling 7,810 shares and now holding 45,390 shares valued at $34.63 million. Despite this, analyst sentiment remains largely positive with a "Buy" consensus rating and a target price of $1,174.61. Eli Lilly reported strong Q3 earnings, raised its dividend, and is advancing several pipeline candidates, including a retatrutide obesity study and an FDA Breakthrough Therapy for ovarian cancer.
This article suggests that while Eli Lilly is a leader in the GLP-1 weight loss drug market, its current valuation is extremely high. Investors with a value bias might consider forgotten pharmaceutical stocks like Merck and Bristol Myers Squibb instead. These companies, despite facing patent cliffs, are trading at much lower price-to-earnings ratios and have strong research and development histories.
UNIVEST FINANCIAL Corp increased its stake in Eli Lilly and Company by 24.2% in Q3, now holding 34,297 shares worth $26.17 million. Eli Lilly reported strong Q3 earnings, beating analyst expectations, raising its dividend, and setting positive FY2025 guidance. The company also announced several positive developments including FDA designations and new study launches, alongside some competitive and legal challenges.
Hoth Therapeutics' topical therapy, HT-001, demonstrated a 100 percent response rate in interim phase II data for cancer patients experiencing toxicity symptoms from EGFR inhibitor therapies. The treatment showed significant improvements in oncology toxicity and pruritus, along with rapid onset and durability of response, and was well tolerated by patients. These results highlight HT-001's strong potential as a supportive oncology treatment.
Eli Lilly & Co (LLY) is presented as a strong candidate for income-oriented investors due to its notable dividend, robust financial health, and consistent growth. The company boasts a high ChartMill Dividend Rating of 7/10, supported by a decade of increasing payouts, a manageable 28.3% payout ratio, and strong profitability. While its current yield is modest, its significant stock price gains and growth prospects make it an appealing long-term dividend investment.
iA Global Asset Management Inc. significantly increased its stake in Republic Services, Inc. (NYSE:RSG) by 215.1% in the third quarter, now holding 54,200 shares valued at approximately $12.44 million. Other institutional investors like Vanguard Group, Geode Capital Management, and Norges Bank also hold substantial positions in RSG, with institutional ownership nearing 57.73%. Despite some analysts trimming price targets, the stock maintains a consensus "Moderate Buy" rating with an average target price of $248.86.
Strs Ohio significantly reduced its stake in Eli Lilly and Company by selling 46,646 shares in the third quarter, decreasing its holding by 13.7% to 292,858 shares. Despite this, Eli Lilly remains a top holding for Strs Ohio, accounting for 0.8% of its portfolio. Other institutional investors, such as Vanguard Group Inc. and Laurel Wealth Advisors LLC, substantially increased their holdings in Eli Lilly during the same period.
iA Global Asset Management Inc. significantly increased its stake in Eli Lilly and Company by 8.9% in the third quarter, bringing its total holdings to 25,664 shares valued at over $19.58 million. This comes after Eli Lilly reported strong quarterly earnings, beating analyst expectations, and raised its quarterly dividend. Institutional investors, including Vanguard and Norges Bank, now own 82.53% of the stock, with analysts maintaining an average "Buy" rating.
Sun Pharmaceutical Industries, India's leading drugmaker, has secured regulatory approval to produce and market a generic version of semaglutide, the active ingredient in Novo Nordisk’s Wegovy. This move intensifies competition for pharmaceutical giants Eli Lilly and Novo Nordisk in India's crucial obesity drug market. Sun Pharma plans to launch its generic semaglutide injection, Noveltreat, after the patent expires in March 2026, and a generic version of Ozempic, Sematrinity, after its semaglutide patent expiry.
MannKind Corporation has outlined key FDA catalysts for 2026, including label updates for Afrezza’s adult dosing, a potential pediatric approval for Afrezza by May 29, 2026, and a decision on the FUROSCIX ReadyFlow Autoinjector by July 26, 2026. These regulatory milestones are crucial for expanding MannKind’s market reach and transitioning it into a broader cardiometabolic platform. Investors are weighing these opportunities against the company's high valuation, debt levels, and the potential impact of any regulatory setbacks.
AbbVie successfully navigated a patent cliff a decade ago, leading to a 460% return for its shareholders. The article examines how AbbVie achieved this feat and then turns its attention to Merck and Bristol Myers Squibb, which are anticipated to face similar patent expiration challenges in the near future. The author suggests looking to AbbVie's strategy as a potential model for these upcoming patent cliff divers.
Llamas in Belgium are being utilized by pharmaceutical companies like AstraZeneca, Sanofi, and Eli Lilly for their unique antibodies, known as nanobodies. These tiny antibodies show promise in developing new treatments for a range of conditions, from cancer to pain management. The article highlights the scientific application of these animals, moving beyond traditional perceptions to leverage their biological advantages in drug discovery.
Ventyx Biosciences' board and compensation committee have approved cash bonus awards for executives and employees in anticipation of its merger with Eli Lilly and Company. These awards replace the 2026 annual equity grants and are contingent on continuous service until the merger closes, which must occur by April 7, 2027. The article also notes that Eli Lilly intends to acquire Ventyx for $1.2 billion, prompting several analyst downgrades for Ventyx.
Ventyx Biosciences' board approved special 2026 cash bonuses for key executives, including CEO Raju Mohan, to replace regular equity grants amidst an anticipated merger with Eli Lilly and Company. These bonuses will accrue monthly until the merger closes, with potential payouts between $449,000 and $2.0 million, and are designed to retain senior leadership during this transition. If the merger is delayed, stock options are expected to be recommended instead.
Ventyx Biosciences' board and compensation committee have approved cash bonus awards for key executives and employees in anticipation of its merger with Eli Lilly and Company. These bonuses replace the regular 2026 annual equity grants and are contingent upon continuous service until the merger's closing, expected by April 7, 2027. The move follows Eli Lilly's announced acquisition of Ventyx for approximately $1.2 billion, leading to downgrades in Ventyx's stock rating by several analyst firms.
Amgen has partnered with Ro to launch a new program providing patients with access to Amgen's GLP-1 therapies for obesity, if approved. This collaboration aims to offer comprehensive care, including medication, coaching, and support, following a doctor's consultation. Ro's Body Program currently serves patients access to Novo Nordisk's Wegovy and Zepbound.
Novo Nordisk's Wegovy, an obesity drug, has received accelerated FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 treatment for this liver condition. The approval, based on positive ESSENCE trial results, caused Novo Nordisk's shares to rise nearly 4%, with Wegovy expected to significantly boost company revenue from MASH treatments. Several ETFs holding Novo Nordisk stock, such as Roundhill GLP-1 & Weight Loss ETF, Amplify Weight Loss Drug & Treatment ETF, and VanEck Pharmaceutical ETF, are anticipated to benefit from this development.
Scott+Scott Attorneys at Law LLP is investigating Eli Lilly and Company's directors and officers for alleged breach of fiduciary duties. This investigation stems from a lawsuit filed by the Indiana Attorney General's office against Eli Lilly on December 31, 2025, concerning an alleged scheme to artificially inflate insulin prices. Shareholders of Eli Lilly are being offered options to discuss the investigation and their potential legal claims.
HC Wainwright has lowered its FY2025 EPS estimate for Septerna (NASDAQ: SEPN) to ($1.53) from ($1.45) but maintained a "Buy" rating and a $35 price target. This revision follows Septerna's recent quarterly earnings miss, where it reported ($0.09) EPS against a $0.19 consensus and $21.5M revenue versus $24.5M. Despite the negative forecast, the overall analyst sentiment remains a "Moderate Buy" with an average price target of $33.83.
Simplicity Wealth LLC reduced its stake in Eli Lilly and Company (LLY) by 36.3% in the third quarter, selling 4,466 shares. Despite this, other institutional investors increased their holdings, and the stock shows strong performance with a recent dividend increase and positive news regarding its pipeline and FDA designations. Analysts maintain a "Buy" consensus with an average target price of $1,174.61 for the company.
Johnson & Johnson projects its 2026 sales to reach around $100 billion for the first time, following a strong performance driven by a 9.1% revenue growth in Q4 and a 10% rise in innovative medicines sales, particularly cancer drugs. Despite a recent drug pricing deal with the Trump administration and ongoing legal liabilities related to talc products, J&J is optimistic about its oncology pipeline and new therapies like icotrokinra, even as investor enthusiasm remains muted. The company aims to become the largest oncology player with over $50 billion in cancer drug sales by 2030.
MBX Biosciences, Inc., a biopharmaceutical company, has appointed Laurie Stelzer as an independent director to its Board of Directors and as the chairperson of the audit committee. Stelzer brings extensive executive and financial leadership experience, with prior roles as CFO at several biotechnology companies and current board positions. Her expertise is expected to be valuable as MBX Biosciences advances its pipeline of precision peptide therapies.
Vest Financial LLC increased its stake in Eli Lilly and Company by 23.8%, purchasing an additional 2,178 shares, bringing their total holdings to 11,328 shares valued at $8.643 million. Wall Street analysts maintain a positive outlook with a consensus "Buy" rating and a target price of $1,174.61. Eli Lilly recently reported strong quarterly earnings, beating estimates with $7.02 EPS and $17.6 billion in revenue, and raised its quarterly dividend.
Illumina Inc. (ILMN) recently hit a 52-week high of $151.35, with InvestingPro data showing a subsequent rise to $163.78. This achievement follows a substantial 80.18% gain over the past six months and comes after the company reported a 5% revenue increase for Q4 2025 and secured reimbursement approval for its TruSight Oncology Comprehensive test. Stifel maintained a Buy rating, raising its price target to $155, while Illumina also launched new initiatives for AI-driven drug discovery and multiomic data analysis.
Stoke Therapeutics (STOK) announced faster enrollment and a clearer data timeline for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, alongside ongoing FDA discussions for expedited review. Despite a strong 194.41% one-year return, the stock's 41.5x P/E ratio is considered overvalued compared to the biotech industry average, though a DCF model suggests it might be significantly undervalued. Investors are encouraged to assess the risks and potential and use various valuation models to form their own narrative.
Bey Douglas LLC significantly reduced its stake in Eli Lilly and Company by 23.2% in Q3, selling 1,467 shares to hold 4,850 shares valued at $3.70 million. Despite this, other major institutions like Vanguard Group, Laurel Wealth Advisors, and Norges Bank increased or initiated substantial positions in LLY, with institutional investors owning 82.53% of the stock. Eli Lilly reported strong financial results, including a Q3 EPS beat and 53.9% revenue growth, and received an FDA Breakthrough Therapy designation for its ovarian cancer candidate, while also increasing its quarterly dividend.
Bristol-Myers Squibb (BMY) has partnered with Microsoft for AI-driven lung cancer detection, marking a strategic move into digital health. Despite a recent 90-day stock jump, its 18.4x P/E ratio suggests undervaluation compared to industry peers and its estimated fair P/E. A more optimistic DCF model indicates a significant undervaluation with a potential fair value of US$126.88 per share.
Wellgistics Health, a leader in health information technology, reported a significant net operating loss of $33.878 million in Q3 2025, primarily due to increased stock-based compensation related to a pre-IPO acquisition. Interim-CEO Prashant Patel highlighted strategic shifts, including focusing sales on their EinsteinRx™ AI pharmacy hub for the Type 2 diabetes market and plans to optimize healthcare information processing through a blockchain smart contracts platform. The company is also expanding into the GLP-1 and Long COVID markets with new products and partnerships.
Dr. Reddy's Laboratories reported a 4.4% YoY revenue growth to ₹8753.4 crore, driven by strong performance in Europe, India, Russia, and ROW markets. However, the company's EBITDA de-grew by 16% YoY with margins declining by 528 bps to 21.9%, primarily due to increased price erosion in US generics and lower sales of gRevlimid. Despite the margin pressure, the management plans to focus on GLP-1 opportunities, biosimilars, and innovative product launches to mitigate the impact of gRevlimid's genericization.
Eli Lilly and Company's stock price increased by 3.6% on Wednesday to $1,078.9780, driven by positive regulatory and clinical news, including Breakthrough Therapy designation for sofetabart and progress in its obesity and pain pipelines. Analysts maintain a bullish outlook, with a consensus "Buy" rating and an average price target of $1,174.61, following a strong Q4 beat and elevated dividend. The company's diverse pipeline and GLP-1 leadership are key growth drivers, despite competitive pressures and minor analyst target adjustments.
Pfizer recently secured a licensing deal with Novavax for its Matrix-M vaccine adjuvant technology, aiming to enhance future vaccines. This deal is seen as an incremental broadening of Pfizer's vaccine toolkit rather than a transformative event, as the company still faces challenges with rebuilding earnings post-pandemic, managing high debt, and addressing patent expirations. Investors are weighing Pfizer's low valuation against dividend strain and pipeline execution risks, with a wide range of fair value estimates.
Eli Lilly's stock saw a 3.5% jump after the FDA granted Breakthrough Therapy designation for its ovarian cancer drug, sofetabart mipitecan, indicating a potentially faster path to market. This positive news follows a recent dip in the stock due to a delayed FDA decision on its oral weight-loss pill. Despite this, Eli Lilly's shares are trading near their 52-week high, reflecting investor interest in its pipeline.
Illumina stock has reached a 52-week high of $151.35, though InvestingPro data shows it has climbed further to $163.78. The company reported a 5% revenue increase in Q4 2025 and secured Medicare reimbursement for its TruSight Oncology test. Stifel raised its price target to $155 with a Buy rating, while Illumina has also launched a large genetic dataset and a cloud-based multiomics platform to support drug discovery.
Biocom will host a distinguished keynote panel at its 2026 Global Partnering & Investor Conference, featuring key leaders in pharmaceutical research and development from AbbVie, Amgen, and Eli Lilly. The conference, held from February 24-26 in La Jolla, California, brings together over 500 investors and executives for discussions, partnering meetings, and networking opportunities. The unscripted panel will explore innovation, AI's role in drug discovery, and collaboration between biotech and large pharmaceutical companies.
Rakuten Investment Management Inc. has initiated a new position in Eli Lilly and Company (NYSE:LLY) by purchasing 30,126 shares valued at approximately $22.99 million in the third quarter. Eli Lilly exceeded Q3 earnings and revenue estimates, reporting $7.02 EPS against $6.42 expected and $17.6 billion in revenue, a 53.9% increase year-over-year. The company also increased its quarterly dividend to $1.73 and received several "Buy" or "Strong-Buy" ratings from Wall Street analysts, with a consensus target price of $1,174.61.
AbbVie (ABBV) is increasing its focus on the burgeoning obesity-treatment market, as revealed at the JPMorgan Healthcare Conference. The company plans to introduce GUBamy, an amylin-mimetic weight-loss drug, aiming to differentiate itself from first-generation GLP-1 therapies by addressing tolerability and durability issues. AbbVie believes its approach, which also helps preserve muscle mass and leverages its aesthetics franchise, will lead to higher patient retention in a market projected to reach $150 billion annually.